[go: up one dir, main page]

PT1170288E - Derivados de difenilureia e a sua utilizacao como antagonistas alfa2/5-ht2c - Google Patents

Derivados de difenilureia e a sua utilizacao como antagonistas alfa2/5-ht2c

Info

Publication number
PT1170288E
PT1170288E PT01401712T PT01401712T PT1170288E PT 1170288 E PT1170288 E PT 1170288E PT 01401712 T PT01401712 T PT 01401712T PT 01401712 T PT01401712 T PT 01401712T PT 1170288 E PT1170288 E PT 1170288E
Authority
PT
Portugal
Prior art keywords
ring
mono
alkyl
dialkylamino
halo
Prior art date
Application number
PT01401712T
Other languages
English (en)
Inventor
Gilbert Lavielle
Olivier Muller
Mark Millan
Mauricette Brocco
Anne Dekeyne
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PT1170288E publication Critical patent/PT1170288E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/201,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
PT01401712T 2000-06-29 2001-06-29 Derivados de difenilureia e a sua utilizacao como antagonistas alfa2/5-ht2c PT1170288E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0008378A FR2810979B1 (fr) 2000-06-29 2000-06-29 Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PT1170288E true PT1170288E (pt) 2004-10-29

Family

ID=8851854

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01401712T PT1170288E (pt) 2000-06-29 2001-06-29 Derivados de difenilureia e a sua utilizacao como antagonistas alfa2/5-ht2c

Country Status (24)

Country Link
US (2) US6784183B2 (pt)
EP (1) EP1170288B9 (pt)
JP (1) JP3933889B2 (pt)
KR (1) KR100485018B1 (pt)
CN (1) CN1241916C (pt)
AR (1) AR033379A1 (pt)
AT (1) ATE273283T1 (pt)
AU (1) AU780022B2 (pt)
BR (1) BR0102607A (pt)
CA (1) CA2352405C (pt)
DE (1) DE60104776T2 (pt)
DK (1) DK1170288T3 (pt)
EA (1) EA005128B1 (pt)
ES (1) ES2227088T3 (pt)
FR (1) FR2810979B1 (pt)
HK (1) HK1042698B (pt)
HU (1) HUP0102723A3 (pt)
NO (1) NO320310B1 (pt)
NZ (1) NZ512658A (pt)
PL (1) PL348392A1 (pt)
PT (1) PT1170288E (pt)
SI (1) SI1170288T1 (pt)
TR (1) TR200402069T4 (pt)
ZA (1) ZA200105394B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200930291A (en) * 2002-04-29 2009-07-16 Bayer Cropscience Ag Pesticidal heterocycles
US20060229335A1 (en) * 2002-12-24 2006-10-12 Bradley Teegarden Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
CA2767153A1 (en) * 2003-02-20 2004-09-02 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists
MY141862A (en) 2003-07-22 2010-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
FR2859723B1 (fr) * 2003-09-16 2005-10-21 Servier Lab Nouveaux derives de benzoindoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2004274183B8 (en) 2003-09-25 2011-04-28 Dompe' Farmaceutici S.P.A. Amidines and derivatives thereof and pharmaceutical compositions containing them
EP1727803B3 (en) * 2004-03-23 2014-04-23 Arena Pharmaceuticals, Inc. Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl] ureas and intermediates thereof
PE20061130A1 (es) * 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
WO2006060762A2 (en) * 2004-12-03 2006-06-08 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2006076592A1 (en) 2005-01-14 2006-07-20 Cgi Pharmaceuticals, Inc. 1,3 substituted diaryl ureas as modulators of kinase activity
EP1843762A1 (en) * 2005-01-19 2007-10-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
WO2007136703A1 (en) 2006-05-18 2007-11-29 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
USRE45337E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
AU2007254255B2 (en) 2006-05-18 2013-03-07 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
CN100390150C (zh) * 2006-06-05 2008-05-28 吴汝林 盐酸咪唑苯脲的制备方法
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
CA2678069A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
CA2678072A1 (en) 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−HT2Aセロトニン受容体に関連した障害の治療のための5−HT2Aセロトニン受容体のモジュレーターとしてのイミダゾ[1,2−a]ピリジン誘導体
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
EP2364142B1 (en) 2008-10-28 2018-01-17 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
JP6313416B2 (ja) * 2013-03-15 2018-04-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Ido阻害剤
TWI704145B (zh) * 2015-06-05 2020-09-11 芬蘭商奧利安公司 新醫藥化合物
CA2989343A1 (en) 2015-06-12 2016-12-15 Yandong Wen Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
PL248268B1 (pl) * 2023-04-13 2025-11-17 Univ Medyczny W Lublinie 1-(1-fenyloimidazolin-2-ylo)-3-aryloalkilo pochodne mocznika oraz sposób ich wytwarzania i ich zastosowanie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR7909023A (pt) * 1979-08-23 1981-06-09 Caterpillar Tractor Co Dispositivos antitorcao para lagartas para veiculos do tipo de rastos e metodo
GB9313913D0 (en) * 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds
US5905080A (en) * 1993-08-20 1999-05-18 Smithkline Beecham, P.L.C. Amide and urea derivatives as 5HT1D receptor antagonists
GB9420999D0 (en) * 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
WO1998024785A1 (en) * 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Indole-urea derivatives with 5-ht antagonist properties
EP0975614A1 (en) * 1997-04-18 2000-02-02 Smithkline Beecham Plc A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity

Also Published As

Publication number Publication date
HUP0102723A3 (en) 2002-11-28
HK1042698A1 (en) 2002-08-23
DE60104776D1 (de) 2004-09-16
PL348392A1 (en) 2002-01-02
CA2352405A1 (fr) 2001-12-29
NO20013254L (no) 2001-12-31
NO320310B1 (no) 2005-11-21
AU780022B2 (en) 2005-02-24
US20040224993A1 (en) 2004-11-11
EP1170288A2 (fr) 2002-01-09
BR0102607A (pt) 2002-05-28
DE60104776T2 (de) 2005-09-01
HK1042698B (zh) 2006-08-11
DK1170288T3 (da) 2004-11-29
KR20020002249A (ko) 2002-01-09
EP1170288A3 (fr) 2002-01-16
JP2002037778A (ja) 2002-02-06
CA2352405C (fr) 2006-10-03
EA200100600A2 (ru) 2002-02-28
FR2810979A1 (fr) 2002-01-04
TR200402069T4 (tr) 2004-09-21
ES2227088T3 (es) 2005-04-01
CN1241916C (zh) 2006-02-15
EP1170288B1 (fr) 2004-08-11
HU0102723D0 (en) 2001-08-28
CN1337395A (zh) 2002-02-27
AR033379A1 (es) 2003-12-17
NO20013254D0 (no) 2001-06-28
US6784183B2 (en) 2004-08-31
SI1170288T1 (en) 2004-12-31
US20020025965A1 (en) 2002-02-28
EA200100600A3 (ru) 2002-04-25
AU5414401A (en) 2002-01-03
EP1170288B9 (fr) 2005-01-26
ZA200105394B (en) 2002-01-31
US7026357B2 (en) 2006-04-11
FR2810979B1 (fr) 2002-08-23
HUP0102723A2 (hu) 2002-03-28
NZ512658A (en) 2002-10-25
JP3933889B2 (ja) 2007-06-20
ATE273283T1 (de) 2004-08-15
KR100485018B1 (ko) 2005-04-25
EA005128B1 (ru) 2004-12-30

Similar Documents

Publication Publication Date Title
PT1170288E (pt) Derivados de difenilureia e a sua utilizacao como antagonistas alfa2/5-ht2c
ATE390404T1 (de) Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
EA200100970A1 (ru) Аминопроизводные как ингибиторы протеазы
FI98367B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten trisyklisten, typpipitoisten yhdisteiden valmistamiseksi
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
DK260588D0 (da) Heterocykliske ketoner
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
PT1307455E (pt) Inibidores de adesao celular mediada por (alfa)l (beta)2
EP1167366A4 (en) AMIN DERIVATIVES
DE3853577D1 (de) Benzyliden-Malononitril-Derivate zur Hemmung von proliferativen Prozessen in Säugetierzellen.
EA199900608A1 (ru) Новые ингибиторы фарнезилтрансферазы, способы их получения, содержащие их фармацевтические композиции и их применение для получения медикаментов
EA200100825A1 (ru) Новые 1-арил-4-тиотриазины
DE59814334D1 (de) 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung als Inhibitoren der Leukozytenadhäsion und sie enthaltende pharmazeutische Präparate
ATE402151T1 (de) 2-(arylphenyl)amino-imidazolin-derivate
NZ504316A (en) Pyrimidine substituted carboxylic acid derivatives which have amido side-chains useful as endothelin receptor antagonists
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
ES8606363A1 (es) Un procedimiento de preparar derivados de acido 1-destia-2- tiacefalosporanico
ES2069967T3 (es) 5-piperazinilalquil-1,5-benzotiazepinonas utiles como antagonistas del calcio.
DK0514942T3 (da) Hidtil ukendte benzopyranderivater og fremgangsmåder til fremstilling deraf
ATE62663T1 (de) Indan-derivate, verfahren zu ihrer herstellung und die erhaltenen zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende zusammensetzungen.
FI955604A0 (fi) 3-(indol-3-yyli)propenoiinihappojohdannaiset NMDA-antagonisteina
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
ATE345330T1 (de) Heterozyclische ketonen als npy y5 antagonisten
CA2245926A1 (en) 7-phenyl-1,4-diazepane compounds, process for their preparation, and pharmaceutical compositions containing them